Compositional brain scores capture Alzheimer's disease-specific structural brain patterns along the disease continuum

Abstract

Introduction: Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain volumetric patterns to capture how Alzheimer's disease (AD) and genetics influence brain structure along the disease continuum.

Methods: This study analyzed data from participants across the AD continuum from the Alzheimer's and Families (ALFA) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies. Compositional data analysis (CoDA) was exploited to examine relative brain volumetric variations that (1) were linked to different AD stages compared to cognitively unimpaired amyloid-β-negative (CU A-) individuals and (2) varied by AD genetic risk.

Results: Disease stage-specific compositional brain scores were identified, differentiating CU A- individuals from those in more advanced stages. Genetic risk-stratified models revealed a broader genetic landscape affecting brain morphology in AD, beyond the well-known apolipoprotein E ε4 allele.

Discussion: CoDA emerges as an alternative multivariate framework to deepen understanding of AD-related structural changes and support targeted interventions for those at higher genetic risk.

Highlights: Compositional data analysis (CoDA) revealed the relative variation of brain region volumes, captured in compositional brain scores, capable of discerning between cognitively unimpaired amyloid-β-negative individuals and subjects within other disease-stage groups along the Alzheimer's disease (AD) continuum. CoDA also uncovered the genetic vulnerability of specific brain regions at each stage of the disease along the continuum. CoDA is capable of integrating magnetic resonance imaging data from two different cohorts without stringent requirements for harmonization. This translates as an advantage, compared to traditional methods, and strengthens the reliability of cross-study comparisons by standardizing the data despite different labeling agreements, facilitating collaborative and large-scale research. The algorithm is sensitive to AD-specific effects, as the main compositional brain scores display little overlap with the age-specific compositional brain score. CoDA provides a more accurate analysis of brain imaging data addressing its compositional nature, which can influence the development of targeted approaches, opening new avenues for enhancing brain health.

Keywords: Alzheimer's disease genetic predisposition; brain imaging genetics; compositional brain score; compositional data analysis; multi phenotype analysis; neurodegeneration; polygenic risk scoring.

FIGURE 1

Workflow coda4microbiome algorithm: implementation in the proposed brain imaging genetics study. AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; ALFA, Alzheimer's and Families study; MCI, mild cognitive impairment; PRS, polygenic risk score; SNP, single nucleotide polymorphism.

FIGURE 2

Compositional brain scores associated with increased odds of belonging to non‐CU A− groups at different AD stages. Regions in dark pink indicate positive contributions to the compositional brain scores, while regions in dark green indicate negative contributions. AD, Alzheimer's disease; AD A+, Alzheimer's disease amyloid‐β–positive individuals; CU A−, cognitively unimpaired amyloid‐β–negative individuals; CU A+, cognitively unimpaired amyloid‐β–positive individuals; MCI A+, mild cognitive impaired amyloid‐ beta–positive individuals.

FIGURE 3

Compositional brain scores associated with increased odds of belonging to the non‐CU A− group stratifying by AD risk profile at different AD stages. Regions in dark pink indicate positive contributions to the compositional brain scores, while regions in dark green indicate negative contributions. AD, Alzheimer's disease; AD A+, Alzheimer's disease amyloid‐β‐–positive individuals; CU A−, cognitively unimpaired amyloid‐β–negative individuals; CU A+, cognitively unimpaired amyloid‐β–positive individuals; MCI A+, mild cognitive impaired amyloid‐β–positive individuals.